Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease

被引:157
|
作者
Drozdzik, M
Bialecka, M
Mysliwiec, K
Honczarenko, K
Stankiewicz, J
Sych, Z
机构
[1] Pomeranian Med Univ, Dept Pharmacol, PL-70111 Szczecin, Poland
[2] Pomeranian Med Univ, Dept Neurol, Szczecin, Poland
[3] Pomeranian Med Univ, Dept Hyg & Epidemiol, Szczecin, Poland
[4] Cty Hosp, Dept Neurol, Szczecin, Poland
来源
PHARMACOGENETICS | 2003年 / 13卷 / 05期
关键词
P-glycoprotein; MDR1; polymorphism; Parkinson's disease;
D O I
10.1097/01.fpc.0000054087.48725.dg
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
P-glycoprotein is a membrane protein encoded by the MDR1 gene, which demonstrates functional polymorphism. It is present in endothelial cells of the blood-brain barrier, thus limiting accumulation of its substrates in the central nervous system. Many epidemiological studies suggest an association between pesticides, which are substrates for P-glycoprotein, and Parkinson's disease. It was hypothesized that polymorphism of the MDR1 gene could modulate interindividual susceptibility for the disease in subjects exposed to pesticides. In a pilot case-control study involving 107 Parkinson's disease patients (30 early onset and 77 late onset patients; 59 exposed to pesticides and 48 non-exposed) and 103 controls, C3435T polymorphism of the gene was analysed. No statistically significant correlation between MDR1 gene polymorphism and Parkinson's disease was found. The 3435TT genotype was noted more frequently, but not significantly, in patients with early onset compared to late onset disease (23.3% versus 10.4%, respectively). A significant association between patients with parkinsonism exposed to pesticides and C3435T polymorphism of the MDR1 gene was found. Comparing the exposed and non-exposed patients, a statistically higher frequency of heterozygous subjects was observed (72.9% versus 47.9%, respectively). This genotype was associated with a significant, almost three-fold increased risk of disease. Similarly, a higher frequency of 3435TT subjects was revealed in exposed subjects (15.5%) compared to non-exposed patients (12.5%). In exposed versus non-exposed subjects, patients carrying at least one 3435T allele (i.e. homozygous and heterozygous) had a significant, five-fold higher risk of Parkinson's disease. Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading to Parkinson's disease.
引用
收藏
页码:259 / 263
页数:5
相关论文
共 50 条
  • [1] Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients
    Mateusz Kurzawski
    Marek Droździk
    Janina Suchy
    Grzegorz Kurzawski
    Monika Białecka
    Wanda Górnik
    Jan Lubiński
    European Journal of Clinical Pharmacology, 2005, 61 : 389 - 394
  • [2] Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients
    Kurzawski, M
    Drozdzik, M
    Suchy, J
    Kurzawski, G
    Bialecka, M
    Górnik, W
    Lubinski, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (5-6) : 389 - 394
  • [3] P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth
    Drozdzik, M
    Mysliwiec, K
    Lewinska-Chelstowska, M
    Banach, J
    Drozdzik, A
    Grabarek, J
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2004, 31 (09) : 758 - 763
  • [4] Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population
    Kotrych, Katarzyna
    Sulikowski, Tadeusz
    Domanski, Leszek
    Bialecka, Monika
    Drozdzik, Marek
    PHARMACOLOGICAL REPORTS, 2007, 59 (02) : 199 - 205
  • [5] Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
    Cascorbi, I
    Gerloff, T
    Johne, A
    Meisel, C
    Hoffmeyer, S
    Schwab, M
    Schaeffeler, E
    Eichelbaum, M
    Brinkmann, U
    Roots, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 169 - 174
  • [6] Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease
    Furuno, T
    Landi, MT
    Ceroni, M
    Caporaso, N
    Bernucci, I
    Nappi, G
    Martignoni, E
    Schaeffeler, E
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    PHARMACOGENETICS, 2002, 12 (07): : 529 - 534
  • [7] P-glycoprotein functions and substrates: Possible roles of MDR1 gene in the kidney
    Ernest, S
    Bello-Reuss, E
    KIDNEY INTERNATIONAL, 1998, : S11 - S17
  • [8] ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO THE MDR1 GENE (P-GLYCOPROTEIN)
    CLUGSTON, C
    BROWN, R
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 496 - 496
  • [9] Relationship of MDR1 gene polymorphism and P-glycoprotein expression in Chinese refractory lupus nephritis
    Jun Zhou
    Hua Lin
    Ju Chen
    Biologia, 2021, 76 : 367 - 374
  • [10] Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein
    Kurata, Y
    Ieiri, I
    Kimura, M
    Morita, T
    Irie, S
    Urae, A
    Ohdo, S
    Ohtani, H
    Sawada, Y
    Higuchi, S
    Otsubo, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (02) : 209 - 219